Keyword: GW Pharmaceuticals
The failure of the study to hit a single goal or show a dose response raises big doubts about the prospects of the drug.
The early look at the pharmacokinetics achieved by delivering CBD and THC via Intec’s Accordion Pill encouraged the biotech to talk up further trials.
GW Pharma's cannabis-based epilepsy treatment Epidiolex is firmly on track for a filing in the U.S. after new data published in the New England Journal of Medicine showed impressive effects on seizure rates.
Bristol-Myers tapped Thomas Lynch as new CSO, Karaboutis joined a long list of execs who had left Biogen, and Editas bid farewell to its very first employee and COO Glucksmann.
After failing in an ulcerative colitis test a few years back, GW Pharma’s cannabis-derived orphan drug treatment has had better luck in a small oncology study for an aggressive type of brain tumor.
GW Pharma has clocked a third set of positive pivotal trial data, which makes it an even more attractive potential purchase.
GW Pharmaceuticals gained about $500 million in market cap on rumors that it may soon be acquired.
British cannabinoid company GW Pharmaceuticals was up about 15% in early trading on news that its lead candidate, Epidiolex (cannabidiol or CBD), had positive Phase III data in the treatment of a rare and severe kind of epilepsy.